Succinct and Royal Marsden launch new partnership
pharmafile | January 29, 2013 | News story | Medical Communications, Research and Development, Sales and Marketing | NHS, Succinct, royal marsden
Communications agency Succinct has unveiled a new innovative NHS/industry partnership with The Royal Marsden hospital, one of Europe’s leading cancer centres.
The aim is to share expertise in the non-financial issues central to the introduction of new medicines and healthcare technologies. The partnership has been cemented by joint funding for a newly created pharmacy post at The Royal Marsden (TRM).
Succint says planning patient access to a new clinical intervention is a complex undertaking, and goes far beyond simply considering cost and health economics. It says increasing emphasis on service delivery and patient pathways means that logistical issues, such as treatment location (hospital or community), clinic organisation/staffing and inpatient bed days must also be considered.
These non-financial issues can lead to considerable delays in the introduction of new treatments, and are a common cause of frustration for healthcare providers, patients and pharma companies.
The TRM/Succinct partnership will feature several programmes, including:
• New medicines service delivery advice sheets – setting out the potential service impact of pipeline medicines 18 months before their anticipated marketing authorisation, available electronically for distribution nationwide
• Industry preceptorships – regular days for industry personnel to visit TRM and gain insight into the roles and responsibilities of staff
• Pharmacist training days – to help TRM pharmacists understand the roles and responsibilities of pharmaceutical industry personnel.
Cathy Wright, director of Succinct Market Access & Value at Succinct, said: “We are proud to have formed what we believe is a unique partnership between a medical education agency and an NHS organisation.
“Through this working relationship with a world-class cancer centre, we hope to further develop our expertise in market access, and offer programmes that enhance communication and understanding between the pharmaceutical industry and healthcare providers.”
She added: “Our clients will benefit from our TRM pharmacy expertise, providing the insight needed to develop both standard and bespoke market access initiatives.”
Related Content
A community-first future: which pathways will get us there?
In the final Gateway to Local Adoption article of 2025, Visions4Health caught up with Julian …
The Pharma Files: with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust
Pharmafile chats with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust, about …
Is this an Oppenheimer moment for the life sciences industry?
By Sabina Syed, Managing Director at Visions4Health In the history of science, few initiatives demonstrate …
